전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved65 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleMerckApproved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1669Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

bevacizumab (Avastin)

US label: colorectal, non-squamous NSCLC, glioblastoma, renal, cervical and ovarian cancers; regimen-specific indicatio… · VEGF-A

#VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1444Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

rituximab (Rituxan)

US label: non-Hodgkin lymphoma, CLL, rheumatoid arthritis, GPA/MPA and pemphigus vulgaris; population-specific indicati… · CD20

#CD20#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1337Status Approved
AntibodyCurated CoreFDAstaleBristol Myers SquibbApproved

nivolumab (Opdivo, BMS-936558)

Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1280Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

trastuzumab (Herceptin, Ogivri, Herzuma)

HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma · HER2

#HER2#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1100Status Approved
AntibodyCurated CoreFDAstaleEli LillyApproved

cetuximab (Erbitux)

US label: head and neck squamous cell cancer and biomarker-selected colorectal cancer; regimen-specific indications · EGFR

#EGFR#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 942Status Approved
AntibodyCurated CoreFDAstaleAstraZenecaApproved

durvalumab (Imfinzi, MEDI4736)

NSCLC (Stage III consolidation), SCLC, biliary tract, HCC · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 750Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
AntibodyCurated CoreFDAstaleAbbVieApproved

adalimumab (Humira, Hyrimoz, Amjevita)

Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA · TNF-α

#TNF-#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 574Status Approved
AntibodyCurated CoreFDAstaleJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 454Status Approved
AntibodyCurated CoreFDAstaleNovo NordiskApproved

semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535)

Type 2 diabetes, chronic weight management, CV risk reduction (T2D) · GLP-1 receptor

#GLP-1receptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 410Status Approved
AntibodyCurated CoreFDAstaleSanofiApproved

dupilumab (Dupixent, REGN668)

Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis · IL-4Rα

#IL-4R#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 278Status Approved
AntibodyCurated CoreFDAstaleEli LillyApproved

tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176)

Type 2 diabetes, chronic weight management · GLP-1 / GIP receptor

#GLP-1GIPreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 269Status Approved
AntibodyCurated CoreFDAstaleRegeneronApproved

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Zaltrap)

Wet AMD, DME, RVO, diabetic retinopathy · VEGF-A / VEGF-B / PIGF

#VEGF-AVEGF-BPIGF#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 244Status Approved
ADCCurated CoreFDAstaleDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, TDxd)

HER2-positive breast cancer (including regimen-specific first-line and early-stage indications); HER2-low/ultralow brea… · HER2

#HER2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 243Status Approved
ADCCurated CoreFDAstaleGileadSN-38 (topoisomerase I inhi…Approved

sacituzumab govitecan-hziy (Trodelvy, IMMU-132, sacituzumab-govitecan-hziy)

TNBC: regimen-specific first-line and previously treated indications; HR-positive/HER2-negative breast cancer after spe… · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 242Status Approved
AntibodyCurated CoreFDAstaleAmgenApproved

etanercept (Enbrel, TNFR-Fc)

RA, PsA, AS, plaque psoriasis, JIA · TNF (decoy receptor)

#TNFdecoyreceptor#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 236Status Approved
AntibodyCurated CoreFDAstaleRocheApproved

ranibizumab (Lucentis, Byooviz, Cimerli)

Wet AMD, DME, RVO, myopic CNV · VEGF-A

#VEGF-A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 234Status Approved
AntibodyCurated CoreFDAstaleNovartisApproved

secukinumab (Cosentyx, AIN457)

Psoriasis, PsA, AS, nr-axSpA, HS · IL-17A

#IL-17A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 229Status Approved
AntibodyCurated CoreFDAstaleBeOne MedicinesApproved

tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr)

Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 213Status Approved

1 / 4 pages

← PreviousNext →